Bristol-Myers Squibb’s (BMS) shares declined today over 4% as Wall Street opened as a consequence of the presentation by partner Nektar Therapeutics at the ASCO Congress which is closing today in Chicago. Nektar presented the first data related to the…
Nektar Therapeutics
Bristol-Myers Squibb is pursuing M&A again: yesterday, in the late evening, it announced an agreement with Nektar Therapeutics, expanding the existing strategic collaboration agreement signed in 2016 by the two companies for the scientific and commercial development of immunotherapy NKTR-214…
US biotech company Nektar Therapeutics yesterday announced the results from the SUMMIT-07 Phase III trial designed to assess the analgesic NKTR-181, a first-in-class opioid providing pain relief without generating euphoria, which would lead to addiction. Such results are highly positive…